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Extracorporeal membrane oxygenation (ECMO) is a technique used for tempo-
rary support of patients with end-stage heart or lung failure. This review will focus 
on the venoarterial ECMO system and its use as a bridge to other long-term durable 
devices and/or cardiac transplantation. It can be used as a bridge to decision because 
it helps to gain time to stabilize the patient for further evaluation for long-term 
treatment such as durable mechanical circulatory pumps or transplantation. ECMO 
is evolving as a treatment for patients waiting on the transplant list. Increasing 
utilization of ECMO in adults has revealed some of the common complications such 
as bleeding and coagulopathy which impact survival in this patient population. The 
use of VA ECMO as a technique for rescuing patients from cardiogenic shock is very 
attractive. However, considering the extensive set of complications and the mortal-
ity it brings with it makes it a less attractive option as a direct bridge to cardiac 
transplant. The literature currently on this subject is very scanty and limited to a 
few studies of small numbers of patients. Further definitive research is needed for 
consensus on the role of VA ECMO as a bridge to cardiac transplant.
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1. Introduction
Extracorporeal membrane oxygenation (ECMO) is a technique used for tem-
porary support of patients with end-stage heart or lung failure. It can be used as a 
bridge to decision because it helps to gain time to stabilize the patient for further 
evaluation for long-term treatment such as durable mechanical circulatory pumps 
or transplantation. The use of ECMO as a direct bridge to cardiac transplantation 
may unmask the complications in these critically ill patients leading to unfavorable 
posttransplant outcomes in some instances; however, it is now becoming the main-
stay of treatments for patients waiting on the transplant list. The history of ECMO 
starts with the advent of the heart-lung machine invented by Gibbon [1, 2]. Further 
modifications leading to devices that are sustainable for longer periods of time gave 
rise to the technique of ECMO used today [3–5].
The use of ECMO in humans was first initiated in the pediatric population [3, 4]. 
Adult ECMO gained importance and is being used increasingly since the first ran-
domized clinical trial by Peek et al. which showed a positive outcome in adults with 
respiratory failure [6]. This has been followed by many reports of success in H1N1 
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influenza patients [7]. Anselmi et al. recently reported the use of ECMO in pregnant 
patients [8]. Increasing utilization of ECMO in adults has revealed some of the com-
mon complications such as bleeding and coagulopathy which impact survival in this 
patient population. The delicate balance between adequate anticoagulation and bleed-
ing complications presents one of the greatest challenges of ECMO therapy today.
The ELSO (Extracorporeal Life Support Organization) was established in 1989. 
The ELSO was formed as an offshoot of a study group that began in 1984 discussing 
cases. The ELSO focuses on collection and sharing of data and has fostered a rich 
collaboration among the majority of centers performing ECMO. The ELSO has 
hence remained a good resource for surgeons, neonatologists, nurses, perfusionists, 
respiratory therapists, biomedical engineers, critical care physicians, and heart 
failure cardiologists.
A total of 73,000 ECMO procedures were recorded by the ELSO as of early 2016 
of which greater than 25% were performed in adult patients [9]. From 2006 to 2011, 
adult ECMO volumes increased greater than four times in the United States [10]. 
Adult ECMO has increased in volume due to its usefulness in improving survival in 
ARDS (acute respiratory distress syndrome) patients [11]. Additionally, with the 
improvement in technology, highly specialized hospitals have evolved the capabili-
ties to transport critically ill patients from rural areas to their critical care units 
making it possible for rural populations to be able to receive advanced care [12, 13].
This review will focus on the venoarterial ECMO system and its use as a bridge 
to other long-term durable devices and/or cardiac transplantation.
2. The ECMO circuit
The ECMO circuit (Figure 1) in its most basic form consists of a pump that is 
capable of pumping blood it receives from the drainage cannula to the membrane 
oxygenator which then leads to a heat exchanger. The oxygenated temperature-
optimized blood is then returned to the patient by the return cannula. ECMO 
cannulation can be done centrally through the right atrium and ascending aorta or 
peripherally via the femoral artery and vein. The type of cannulation used whether 
central or peripheral influences the outcomes as the complications differ. When 
central cannulation is used, bleeding requiring transfusions is higher. In central 
cannulation higher rates of reoperation are also noted. Increased complications will 
decrease survival and increase resource utilization. On the other hand, peripheral 
cannulation has been noted to produce fewer bleeding complications. It can be 
Figure 1. 
VA-ECMO circuit.
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placed in a shorter time and at the bedside. However, the complication of limb 
ischemia occurs equally in both types of cannulations.
ECMO circuits are set up depending on the organs that need to be bypassed. 
When both heart and lungs have to be bypassed, the venoarterial ECMO 
(VA-ECMO) is used as shown in (Figure 1). The VA-ECMO circuit provides both 
gas exchange and hemodynamic support as blood is pumped from the venous to 
the arterial systems. On the other hand, if only the lungs need to be bypassed, the 
veno-venous circuit (VV-ECMO) facilitates only gas exchange with no hemody-
namic support. In VV-ECMO blood is removed taken out of the venous system and 
oxygenated and pumped back into it.
VA-ECMO is designed to provide cardiac and pulmonary support. Deoxygenated 
blood is drained from the venous system, and oxygenated blood is returned into the 
arterial circulation, in a similar fashion to standard cardiopulmonary bypass. In the 
VA-ECMO system, central cannulation is achieved by draining blood directly from 
the right atrium and returning oxygenated blood to the proximal ascending aorta. 
Peripheral cannulation uses blood drained from the proximal femoral vein/jugular 
vein which is oxygenated and then returned to the carotid/axillary/femoral artery. 
The Seldinger technique is used typically to achieve the cannulations.
Two types of pumps are currently available for use in ECMO circuits. They are 
centrifugal pumps and roller pumps. Centrifugal pumps are smaller and pump 
blood by providing a pressure differential across a pump head that contains a 
magnetically driven impeller revolving at speeds up to 3000 revolutions per min. 
On the other hand, roller pumps push blood across the circuit by progressively 
compressing segments of tubing along a curved pathway. Centrifugal pumps have 
been associated with a lesser degree of hemolysis compared with roller pumps and 
decreased requirement of anticoagulation. Therefore, centrifugal pumps are being 
increasingly used in in adult patients.
3. Indications and contraindications for VA-ECMO
The major indication for VA-ECMO is cardiogenic shock as defined in the ELSO 
guidelines [14]. This includes inadequate tissue perfusion due to hypotension and 
low cardiac output despite volume repletion, inotropes, vasopressors, and intra-
aortic balloon counterpulsation use. Common causes for cardiogenic shock are 
acute myocardial infarction (AMI), myocarditis, peripartum cardiomyopathy, acute 
decompensation of chronic heart failure, and postcardiotomy shock.
Septic shock is an indication in some centers. The guidelines on prognostication 
of survival without ECMO are based on the IABP score in postcardiotomy patients 
[15] and the Samuels score also in postcardiotomy patients [16]. In a retrospective 
analysis, Samuels et al. [16] showed that early insertion of mechanical support 
reduces multi-organ failure in these patients. In hospital mortality, correlates with 
increasing inotropic support needed to get patients off cardiopulmonary bypass fol-
lowing cardiac surgery. The combination of pharmacological criteria together with 
hemodynamic presentation should be used for mechanical support initiation in 
cardiogenic shock. Earlier institution of mechanical support devices tends to lower 
incidence of postoperative multi-organ failure and improve discharge rates [16].
The advantage of VA-ECMO is that it provides quick biventricular support and 
can be achieved at the bedside for poor oxygenation, biventricular failure, refrac-
tory malignant arrhythmias, and heart failure with severe pulmonary failure. 
VA-ECMO can be used as a bridge to recovery, AMI after revascularization, myocar-
ditis, postcardiotomy shock, chronic heart failure, and non-revascularizable AMI.
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ECMO can be used as a bridge to cardiac transplant as well as durable mechani-
cal circulatory support: ventricular assist device (VAD) and the total artificial heart 
(TAH).
The absolute contraindications for VA-ECMO would be unrecoverable heart 
and the patient not being a candidate for cardiac transplant or VAD. Chronic organ 
dysfunctions such as emphysema, cirrhosis, and end-stage renal failure are all 
considered absolute contraindications. Compliance in terms of financial and medi-
cal strategies and cognitive, psychiatric, or social limitations are considered con-
traindications. Prolonged CPR without adequate tissue perfusion is also an absolute 
contraindication.
The relative contraindications for ECMO would be inability to tolerate antico-
agulation, advanced age, and obesity. Advanced age is a gray area as there are no 
defined cutoffs due to lack of existing data in older patients.
4. Complications during VA-ECMO support
Complications encountered during ECMO support include lack of a fine balance 
between anticoagulation and bleeding, limb ischemia, disseminated intravascular 
coagulation (DIC), heparin-induced thrombocytopenia (HIT), bleeding from a 
preexisting surgical site requiring reexploration, and progression of preexisting 
renal failure.
4.1 Anticoagulation and bleeding
Interaction of blood with non-endothelial surfaces leads to inflammation and 
prothrombosis. ECMO therefore leads to consumptive coagulopathy as well as a 
dilution of coagulation factors resulting in decreased fibrinogen levels. The inflam-
matory response secondary to ECMO gives rise to a hypercoagulable state, requiring 
anticoagulation to prevent thrombosis of the circuit. The delicate balance between 
adequate anticoagulation and bleeding complications presents one of the greatest 
challenges of ECMO therapy today. Different anticoagulation protocols are used 
across the centers. Uniformity in these protocols is lacking [17].
ECMO has historically been the mainstay of resuscitation in pediatric care. 
Adult ECMO protocols have hence evolved from the pediatric practice of antico-
agulation in ECMO. Higher flow and larger cannula sizes in adult ECMO contribute 
less to turbulence, stasis, and thrombogenicity. Simple circuits with minimum 
number of connectors create less turbulence, while larger cannulas especially on the 
venous side reduce stasis and thrombogenicity, therefore requiring lower levels of 
anticoagulation. This suggests that anticoagulation protocols used in the pediatric 
population may not be optimal in adults.
Survival on ECMO appears to be more favorable in the younger population, 
and bleeding and coagulopathy appear to be the most common complications 
which raise the question if the coagulation system changes in its character and 
dimensions with advancing age. Interestingly, aging is accompanied by increases in 
plasma concentrations of factors VII and VIII and fibrinogen progressively [18, 19]. 
Coagulation cascade upregulation with age may increase thrombosis in pathologi-
cal states demanding special attention when designing anticoagulation therapy for 
adult and especially older patients on ECMO.
Genetic polymorphisms and ethnic variations further complicate and influence 
drug metabolism and efficacy which need to be accounted for while developing 
anticoagulation protocols and selecting anticoagulants [20]. Clinical significance 
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and predictive value of hypercoagulability markers need to be defined in different 
age groups in prospective studies in order to be able to define optimal anticoagula-
tion regimens. Research is needed in areas of optimizing anticoagulation protocols 
in adults with respect to age, gender, race, ethnicity, and technical aspects. If 
tailored appropriately adult ECMO therapy could probably achieve better success 
with far less aggressive anticoagulation than that used in the pediatric population.
4.2 Roller versus centrifugal pumps
Though centrifugal pumps are increasingly used, they are not without disad-
vantages. Centrifugal pumps are continuous flow pumps (CF pumps) and produce 
shear stress leading to acquired von Willebrand factor deficiency and bleeding 
complications. A recent retrospective analysis demonstrated an increased risk for 
nonsurgical bleeding (gastrointestinal, pulmonary, and neurological) with cen-
trifugal pumps despite lower levels of heparin anticoagulation [21]. This study used 
patients supported on ECMO for 5 days for comparison of bleeding complications 
using centrifugal and roller pumps. The underlying etiology can be multifactorial 
but needs further research for specific delineation of inciting factors.
4.3 Limb ischemia
Femoral arterial cannulation carries an increased risk of profound distal limb 
ischemia. Some of the causes that lead to lower limb ischemia during ECMO sup-
port are acute embolism, dissection/perforation or rupture of the common femoral 
artery (CFA) or the iliac artery, thrombosis, pseudoaneurysm, hyperperfusion, and 
ischemia after decannulation usually due to distal embolization [22]. This problem 
has been solved to a large extent by prophylactically placing an ipsilateral perfusion 
catheter [22]. In a small study using 43 patients who underwent femoral artery can-
nulation, placement of a prophylactic superficial femoral artery [SFA] catheter in 
ten patients produced no limb ischemia. Of the rest of the patients (n = 33) who did 
not receive prophylactic SFA cannulation, seven patients had limb ischemia. Four of 
these patients underwent fasciotomy and decannulation leading to amputation in 
one patient. The three patients who received SFA cannulation for limb ischemia did 
not need amputation [23]. Foley et al. also showed that age was a predictor for limb 
ischemia [23]. Patients who developed limb ischemia were significantly younger 
than those patients without limb ischemia. This has been attributed to the size of 
the arterial cannula with respect to the femoral artery size in younger patients. CFA 
diameter was noted to increase with age. It was considered to be related to BSA and 
gender with increasing diameters found in males and those who have a larger BSA 
[24]. However, the data presented by Foley et al. found no correlation between 
the rate of limb ischemia and BSA, BMI, or size of the cannula as compared to the 
earlier literature [23, 24].
Accurate insertion of the arterial cannula in the CFA is of paramount impor-
tance to minimize risk of ipsilateral limb ischemia. One of the important aspects is 
to avoid improper retrograde SFA cannulation leading to significant flow limitation 
and in extreme cases to complete occlusion. Additionally, measurement of pressure 
in the SFA after placing the patient on ECMO support will identify the patients 
who actually need a catheter for antegrade perfusion [25]. Such an approach 
may reduce the extra effort and insertion of an additional catheter in all patients 
prophylactically.
Considering the limited data in the current literature, the use of prophylactic 
SFA cannulation in younger individuals may be a reasonable approach with or 
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without direct SFA pressure measurements especially if it can be done at the bed-
side. Duplex ultrasonography or direct SFA pressure measurements done at the time 
of ECMO placement may be an alternative to an early decision on which patients 
need the SFA cannulation. The existing literature does not seem to report a direct 
correlation with mortality in these patients which is another area of investigation 
that needs future attention.
4.4 Heparin-induced thrombocytopenia
Thrombocytopenia is a devastating complication in patients on VA-ECMO 
support. The etiology of platelet reduction in ECMO is still ambiguous. HIT 
has been considered one of the causative mechanisms. Current literature has 
very little to offer in this area. The incidence and mortality secondary to HIT in 
VA-ECMO patients is very poorly represented. In a recent retrospective study on 
VA-ECMO patients hospitalized for >3 days with high clinical suspicion of HIT 
and positive anti-PF4/heparin antibodies, the prevalence of HIT in patients on 
VA-ECMO support was estimated as 0.36%. Mortality rate was noted as 33.3%, 
which was not statistically different from the mortality observed in patients on 
VA-ECMO support without HIT [26]. HIT is a complication that appears to have 
a low prevalence; its effects are devastating if untreated. Bivalirudin and argatro-
ban have been used to successfully treat this condition in VA-ECMO patients in 
small studies [27–29]. Further investigations in larger populations are required 
in this patient population for standardized regimens to be incorporated into the 
guidelines.
4.5 Disseminated intravascular coagulation
Extracorporeal cardiopulmonary resuscitation (eCPR) with VA-ECMO has 
become a reality in today’s medicine to rescue patients in refractory cardiac arrest. 
DIC therefore becomes an important issue in this subset of patients who experi-
ence serious abnormalities in coagulation and thrombosis. Survival of adults 
supported by eCPR in adults is lower than that noted in patients supported on 
VA-ECMO [30]. In a retrospective analysis of eCPR patients it was noted they had 
consistently higher DIC scores and the mean DIC scores was significantly different 
between survivors and non-survivors [31]. It may be reasonable to use DIC scores 
in prognostication in these patients. Further studies are warranted in this area. 
Such prognostication remains very important as it can curtail excessive use of blood 
products.
5. ECMO as a bridge to transplantation
Cardiac transplant still remains the gold standard in treatment of end-stage 
heart failure. The scarcity of donors has led to the generation of a whole field of 
mechanical circulatory support devices which has brought in a new era in the 
treatment of advanced heart failure. The use of continuous flow LVADs as a bridge 
to transplantation (BTT) has become more popular and the mainstay of patients 
waiting on the transplant list [32]. More recently, VA-ECMO is being increasingly 
used as a rescue therapy [33, 34] However, this trend has now led to the use of 
ECMO as a direct bridge to transplantation in adults. This seems to be an attractive 
pathway for critically ill advanced heart failure patients waiting on the transplant 
wait list to get a heart very quickly it raises many questions about the feasibility 
of such an approach in the population. Though there is a very small portion of the 
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patients on the wait list who would be bridged directly on VA-ECMO to cardiac 
transplant, the lack of extensive literature and evidence for posttransplant survival 
of patients supported on ECMO makes this proposition questionable. Due to the 
large number of candidates waiting on the transplant list and too many high prior-
ity status 1A candidates in the wait list, the most recent organ allocation system 
has placed VA-ECMO bridge as the highest priority for cardiac transplant on the 
wait list [35]. This has a major disadvantage because of poor early and midterm 
posttransplant survival as compared to patients supported on CF-VADs [36]. It is 
therefore probably too early to use VA-ECMO as the highest priority for transplant 
organ availability/allocation.
BTT in the adult population has remained controversial despite small studies 
reporting varied survival rates posttransplantation in this population. The decision 
to use CF-LVADS as a BTT was based on various studies which showed improve-
ments in functional status and quality of life in this population [37]. Such data is 
lacking in adults supported on VA-ECMO as BTT.
Therefore, the new system of allocation may reduce the transplant wait list 
mortality but may on the other hand increase the posttransplant mortality leading 
to a waste of organs in the setting of donor organ shortage. The most recent large 
retrospective analysis of the UNOS database showed a deceased survival in the 
early/mid posttransplant period [36]. Other studies from different countries have a 
wide variety of data which are limited.
The literature on use of VA-ECMO as a direct bridge to heart transplantation 
in adults is scanty. The use of VA-ECMO in posttransplant primary graft failure 
showed poor outcomes [38–40]. Since patients supported on ECMO are critically 
ill and the time to finding an organ is short, the extensive social and psychological 
evaluation required for transplant evaluation is not possible which could lead to 
suboptimal candidate selection.
Studies from France reported varying survival rates ranging from 51 to 70.4% 
at 1-year posttransplant in patients bridged on VA-ECMO [38, 41, 42]. Some of the 
caveats of these reports are the wait list mortality was not reported in the study 
by Jasseron et al. [38], while the duration of pretransplant ECMO support was not 
reported in the study by Rousse et al. [41] In the study Barth et al. [42], the sur-
vival was 100% at 1-year posttransplant though there were several adverse events 
and the study had a n = 8 with a mean age of 41 years. In a case series reported 
from Taiwan, 73% survived to hospital discharge in a cohort of 15 patients [43]. 
Mishra et al. [44] have reported a 1-year survival of 70%. A small study from 
Spain on posttransplant outcomes of patients bridged on ECMO showed no 
increase in mortality [45]. In France the special urgency wait list did improve the 
wait list mortality but also showed a significant increase in the posttransplant 
mortality [46].
6. Conclusions
The use of VA-ECMO as a technique for rescuing patients from cardiogenic 
shock is very attractive. However, considering the extensive set of complications 
and the mortality it brings with it makes it a less attractive option as a direct bridge 
to cardiac transplant. The literature currently on this subject is very scanty and 
limited to a few studies of small numbers of patients. The existing literature from 
France suggests a higher rate of posttransplant deaths even though the wait list 
mortality was reduced which does not seem to be an optimal way for organ alloca-
tion. In the light of present findings, further definitive research is needed for a 
consensus on the role of VA-ECMO as a bridge to cardiac transplant.
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